Despite the fact that the human papillomavirus (HPV) vaccine has been available in the U.S. for over 10 years and remains the only vaccine to protect against multiple types of cancer, several recent studies show that public knowledge about the vaccine and HPV’s relationship to cancer remains low.
HPV is responsible for 90% of cervical and anal cancers, and 70% of oropharyngeal (throat) cancers.
The first-generation HPV...
A study from researchers at The University of Texas MD Anderson Cancer Center found that the prevalence of the types of oral human papillomavirus...
According to the Centers for Disease Control and Prevention, the human papillomavirus is responsible for roughly 33,700 new cancer cases each...
Despite the availability of vaccines that could prevent the majority of cancers caused by the human papillomavirus (HPV), the incidence of cervical, oropharyngeal, anal, vulvar and vaginal cancers is increasing in the United States.
MD Anderson’s HPV-Related Cancers Moon Shot™ is working to identify practical solutions and strategies to increase vaccination rates, improve screening and diagnostic options, and develop novel...
Researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab on...
The Food and Drug Administration’s (FDA) approval of a new vaccine that targets five additional strains of human papillomavirus (HPV) fortifies...